If you are curious about how your brain really works this is the podcast for you! Hosted by physician Dr. Ginger Campbell (2022 Podcast Hall of Fame) from 2006-2023, Brain Science explores how recent discoveries in neuroscience are unraveling the mystery of how our brain makes us human. It features conversations with leading scientists and philosophers and is "the podcast for everyone who has a brain" because Dr. Campbell makes neuroscience accessible to listeners of all backgrounds. Over 10 ...
…
continue reading
Content provided by PER Spectives and PER® Spectives. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PER Spectives and PER® Spectives or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Similar to PER Podcast Sessions
Emergency Medicine Cases – Where the Experts Keep You in the Know. For show notes, quizzes, videos and more learning tools please visit emergencymedicinecases.com
…
continue reading
The surprising connections in science and technology that give you the Big Picture. Astronomer Seth Shostak and science journalist Molly Bentley are joined each week by leading researchers, techies, and journalists to provide a smart and humorous take on science. Our regular "Skeptic Check" episodes cast a critical eye on pseudoscience.
…
continue reading
Deep in the back of your mind, you’ve always had the feeling that there’s something strange about reality. There is. Join Robert Lamb and Joe McCormick as they examine neurological quandaries, cosmic mysteries, evolutionary marvels and our transhuman future.
…
continue reading
The Naked Scientists flagship science show brings you a lighthearted look at the latest scientific breakthroughs, interviews with the world's top scientists, answers to your science questions and science experiments to try at home.
…
continue reading
Help me fill in the blanks of the practice of ED Critical Care. In this podcast, we discuss all things related to the crashing, critically ill patient in the Emergency Department. Find the show notes at emcrit.org.
…
continue reading
Hosted by former Marvel entertainment lawyer Paul Sarker and entertainment enthusiast Mesh Lakhani, Better Call Paul will delve into the business and legal issues at play behind the glitz and glam. This show takes you beyond the catchy headlines to find out what’s really at play behind the scenes and gives you an introduction to the business side of show business.
…
continue reading
This podcast might not actually kill you, but Erin Welsh and Erin Allmann Updyke cover so many things that can. In each episode, they tackle a different topic, teaching listeners about the biology, history, and epidemiology of a different disease or medical mystery. They do the scientific research, so you don’t have to. Since 2017, Erin and Erin have explored chronic and infectious diseases, medications, poisons, viruses, bacteria and scientific discoveries. They’ve researched public health ...
…
continue reading
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
))
S2 Ep38: Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer
Manage episode 497490165 series 2987803
Content provided by PER Spectives and PER® Spectives. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PER Spectives and PER® Spectives or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Thank you for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Rachel N. Grisham, MD; Oladapo O. Yeku, MD, PhD, FACP; and Ramez N. Eskander, MD, explore new frontiers in the treatment of ovarian cancer, including advances in biomarker-driven decision-making, maintenance strategies, and emerging targeted therapies. The discussion covers the evolving role of PARP inhibitors, the impact of HRD and BRCA testing, and the integration of antibody-drug conjugates into treatment plans for patients with recurrent disease.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
1. Assess the role of molecular and biomarker testing—including BRCA, HRD, and FRα—in guiding personalized treatment decisions and optimizing maintenance strategies in ovarian cancer.
2. Incorporate recent clinical trial data on PARP inhibitors, antibody-drug conjugates, and novel combinations to inform the sequencing and integration of emerging therapies into clinical practice.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AbbVie, Inc; and Corcept Therapeutics Incorporated.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6325
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
Episode Description
In this podcast, experts Rachel N. Grisham, MD; Oladapo O. Yeku, MD, PhD, FACP; and Ramez N. Eskander, MD, explore new frontiers in the treatment of ovarian cancer, including advances in biomarker-driven decision-making, maintenance strategies, and emerging targeted therapies. The discussion covers the evolving role of PARP inhibitors, the impact of HRD and BRCA testing, and the integration of antibody-drug conjugates into treatment plans for patients with recurrent disease.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
1. Assess the role of molecular and biomarker testing—including BRCA, HRD, and FRα—in guiding personalized treatment decisions and optimizing maintenance strategies in ovarian cancer.
2. Incorporate recent clinical trial data on PARP inhibitors, antibody-drug conjugates, and novel combinations to inform the sequencing and integration of emerging therapies into clinical practice.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AbbVie, Inc; and Corcept Therapeutics Incorporated.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6325
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair
Rachel N. Grisham, MD
Associate Attending Physician
Division of Solid Tumor Oncology
Section Head, Ovarian Cancer
Director, Gynecologic Medical Oncology, MSK Westchester
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consulting/Advisory Board: AstraZeneca, Corcept, Genmab, GOG Foundation, GSK, Incyclix, Incyte, SpringWorks, Verastem.
Faculty
Ramez N. Eskander, MD
Professor of Gynecologic Oncology
Medical Director, Clinical Trials Office
Fellowship Program Director
UC San Diego Moores Cancer Center
La Jolla, CA
Disclosures: Advisory Board:AbbVie, AstraZeneca, Daiichi Sankyo, Eisai, GSK, MSD, Myriad, Nuvectis, Pfizer, PMV Pharma, Regeneron; Honoraria: MSD.
Oladapo Yeku, MD, PhD, FACP
Assistant Professor
Harvard Medical School
Director of Translational Research, Gynecologic Oncology Program
Massachusetts General Hospital
Boston, MA
Disclosures: Advisory Board Member: HC Bioscience; Contracted Research: Ascendis Pharma, BioNTech, Immunocore Limited, Merck Sharp & Dohme, ProfoundBio
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, has no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information of the live presentation program Show Me the Data New Frontiers in the Treatment of Ovarian Cancer program held on Saturday, May 31, 2025, in Chicago, Illinois, go to https://www.gotoper.com/annual-oncology-meeting-25-ovarian-activity
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Chair
Rachel N. Grisham, MD
Associate Attending Physician
Division of Solid Tumor Oncology
Section Head, Ovarian Cancer
Director, Gynecologic Medical Oncology, MSK Westchester
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consulting/Advisory Board: AstraZeneca, Corcept, Genmab, GOG Foundation, GSK, Incyclix, Incyte, SpringWorks, Verastem.
Faculty
Ramez N. Eskander, MD
Professor of Gynecologic Oncology
Medical Director, Clinical Trials Office
Fellowship Program Director
UC San Diego Moores Cancer Center
La Jolla, CA
Disclosures: Advisory Board:AbbVie, AstraZeneca, Daiichi Sankyo, Eisai, GSK, MSD, Myriad, Nuvectis, Pfizer, PMV Pharma, Regeneron; Honoraria: MSD.
Oladapo Yeku, MD, PhD, FACP
Assistant Professor
Harvard Medical School
Director of Translational Research, Gynecologic Oncology Program
Massachusetts General Hospital
Boston, MA
Disclosures: Advisory Board Member: HC Bioscience; Contracted Research: Ascendis Pharma, BioNTech, Immunocore Limited, Merck Sharp & Dohme, ProfoundBio
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, has no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information of the live presentation program Show Me the Data New Frontiers in the Treatment of Ovarian Cancer program held on Saturday, May 31, 2025, in Chicago, Illinois, go to https://www.gotoper.com/annual-oncology-meeting-25-ovarian-activity
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
60 episodes
Share
Manage episode 497490165 series 2987803
Content provided by PER Spectives and PER® Spectives. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PER Spectives and PER® Spectives or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Thank you for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Rachel N. Grisham, MD; Oladapo O. Yeku, MD, PhD, FACP; and Ramez N. Eskander, MD, explore new frontiers in the treatment of ovarian cancer, including advances in biomarker-driven decision-making, maintenance strategies, and emerging targeted therapies. The discussion covers the evolving role of PARP inhibitors, the impact of HRD and BRCA testing, and the integration of antibody-drug conjugates into treatment plans for patients with recurrent disease.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
1. Assess the role of molecular and biomarker testing—including BRCA, HRD, and FRα—in guiding personalized treatment decisions and optimizing maintenance strategies in ovarian cancer.
2. Incorporate recent clinical trial data on PARP inhibitors, antibody-drug conjugates, and novel combinations to inform the sequencing and integration of emerging therapies into clinical practice.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AbbVie, Inc; and Corcept Therapeutics Incorporated.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6325
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
Episode Description
In this podcast, experts Rachel N. Grisham, MD; Oladapo O. Yeku, MD, PhD, FACP; and Ramez N. Eskander, MD, explore new frontiers in the treatment of ovarian cancer, including advances in biomarker-driven decision-making, maintenance strategies, and emerging targeted therapies. The discussion covers the evolving role of PARP inhibitors, the impact of HRD and BRCA testing, and the integration of antibody-drug conjugates into treatment plans for patients with recurrent disease.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
1. Assess the role of molecular and biomarker testing—including BRCA, HRD, and FRα—in guiding personalized treatment decisions and optimizing maintenance strategies in ovarian cancer.
2. Incorporate recent clinical trial data on PARP inhibitors, antibody-drug conjugates, and novel combinations to inform the sequencing and integration of emerging therapies into clinical practice.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AbbVie, Inc; and Corcept Therapeutics Incorporated.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6325
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair
Rachel N. Grisham, MD
Associate Attending Physician
Division of Solid Tumor Oncology
Section Head, Ovarian Cancer
Director, Gynecologic Medical Oncology, MSK Westchester
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consulting/Advisory Board: AstraZeneca, Corcept, Genmab, GOG Foundation, GSK, Incyclix, Incyte, SpringWorks, Verastem.
Faculty
Ramez N. Eskander, MD
Professor of Gynecologic Oncology
Medical Director, Clinical Trials Office
Fellowship Program Director
UC San Diego Moores Cancer Center
La Jolla, CA
Disclosures: Advisory Board:AbbVie, AstraZeneca, Daiichi Sankyo, Eisai, GSK, MSD, Myriad, Nuvectis, Pfizer, PMV Pharma, Regeneron; Honoraria: MSD.
Oladapo Yeku, MD, PhD, FACP
Assistant Professor
Harvard Medical School
Director of Translational Research, Gynecologic Oncology Program
Massachusetts General Hospital
Boston, MA
Disclosures: Advisory Board Member: HC Bioscience; Contracted Research: Ascendis Pharma, BioNTech, Immunocore Limited, Merck Sharp & Dohme, ProfoundBio
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, has no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information of the live presentation program Show Me the Data New Frontiers in the Treatment of Ovarian Cancer program held on Saturday, May 31, 2025, in Chicago, Illinois, go to https://www.gotoper.com/annual-oncology-meeting-25-ovarian-activity
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Chair
Rachel N. Grisham, MD
Associate Attending Physician
Division of Solid Tumor Oncology
Section Head, Ovarian Cancer
Director, Gynecologic Medical Oncology, MSK Westchester
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consulting/Advisory Board: AstraZeneca, Corcept, Genmab, GOG Foundation, GSK, Incyclix, Incyte, SpringWorks, Verastem.
Faculty
Ramez N. Eskander, MD
Professor of Gynecologic Oncology
Medical Director, Clinical Trials Office
Fellowship Program Director
UC San Diego Moores Cancer Center
La Jolla, CA
Disclosures: Advisory Board:AbbVie, AstraZeneca, Daiichi Sankyo, Eisai, GSK, MSD, Myriad, Nuvectis, Pfizer, PMV Pharma, Regeneron; Honoraria: MSD.
Oladapo Yeku, MD, PhD, FACP
Assistant Professor
Harvard Medical School
Director of Translational Research, Gynecologic Oncology Program
Massachusetts General Hospital
Boston, MA
Disclosures: Advisory Board Member: HC Bioscience; Contracted Research: Ascendis Pharma, BioNTech, Immunocore Limited, Merck Sharp & Dohme, ProfoundBio
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, has no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information of the live presentation program Show Me the Data New Frontiers in the Treatment of Ovarian Cancer program held on Saturday, May 31, 2025, in Chicago, Illinois, go to https://www.gotoper.com/annual-oncology-meeting-25-ovarian-activity
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
60 episodes
All episodes
×
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.
Similar to PER Podcast Sessions
If you are curious about how your brain really works this is the podcast for you! Hosted by physician Dr. Ginger Campbell (2022 Podcast Hall of Fame) from 2006-2023, Brain Science explores how recent discoveries in neuroscience are unraveling the mystery of how our brain makes us human. It features conversations with leading scientists and philosophers and is "the podcast for everyone who has a brain" because Dr. Campbell makes neuroscience accessible to listeners of all backgrounds. Over 10 ...
…
continue reading
Emergency Medicine Cases – Where the Experts Keep You in the Know. For show notes, quizzes, videos and more learning tools please visit emergencymedicinecases.com
…
continue reading
The surprising connections in science and technology that give you the Big Picture. Astronomer Seth Shostak and science journalist Molly Bentley are joined each week by leading researchers, techies, and journalists to provide a smart and humorous take on science. Our regular "Skeptic Check" episodes cast a critical eye on pseudoscience.
…
continue reading
Deep in the back of your mind, you’ve always had the feeling that there’s something strange about reality. There is. Join Robert Lamb and Joe McCormick as they examine neurological quandaries, cosmic mysteries, evolutionary marvels and our transhuman future.
…
continue reading
The Naked Scientists flagship science show brings you a lighthearted look at the latest scientific breakthroughs, interviews with the world's top scientists, answers to your science questions and science experiments to try at home.
…
continue reading
Help me fill in the blanks of the practice of ED Critical Care. In this podcast, we discuss all things related to the crashing, critically ill patient in the Emergency Department. Find the show notes at emcrit.org.
…
continue reading
Hosted by former Marvel entertainment lawyer Paul Sarker and entertainment enthusiast Mesh Lakhani, Better Call Paul will delve into the business and legal issues at play behind the glitz and glam. This show takes you beyond the catchy headlines to find out what’s really at play behind the scenes and gives you an introduction to the business side of show business.
…
continue reading
This podcast might not actually kill you, but Erin Welsh and Erin Allmann Updyke cover so many things that can. In each episode, they tackle a different topic, teaching listeners about the biology, history, and epidemiology of a different disease or medical mystery. They do the scientific research, so you don’t have to. Since 2017, Erin and Erin have explored chronic and infectious diseases, medications, poisons, viruses, bacteria and scientific discoveries. They’ve researched public health ...
…
continue reading
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
